Akebia stock: buy or sell?
December 6th, 2019
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
Should I buy Akebia stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Akebia stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Akebia stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we collected 6 ratings published for AKBA stock in the last month. The general sentiment of these ratings is bullish for AKBA stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-5-2||JPMorgan Chase & Co.||n/a||Overweight|
Akebia stock analysis
Akebia Therapeutics shares dropped -2.48% to $5.91 today.
Akebia Therapeutics shares dropped -2.48% to $5.91 today. Since price and SMA200d lines crossed up on Nov/27, AKBA climbed $0.94 (18.91%). From a daily perspective, AKBA is in a short term uptrend after plotting its last bottom ($3.06, on November 19th) higher than the previous bottom, and its last top ($6.56, on November 29th) also over the previous top. Now trading in between its last bottom and last top AKBA might consolidate in a plain range, waiting to break out over $6.56 or down under $3.06.
After boosting a super good 33.07% in a week last week, Akebia closed this week at $5.91 and collapsed a dreadful -6.04%.
Since price and SMA40w lines crossed up last week, AKBA climbed $1.70 (40.38%). Since this week when SMA10w and SMA20w crossed up, AKBA price slipped $-0.38 per share (-6.04%).
Akebia stock price history
Akebia stock went public on March 20th, 2014 with a price of $22.901. Since then, AKBA stock sliced a -74.20%, with a yearly average of -14.80%.
1: Adjusted price after possible price splits or reverse-splits.
Akebia stock historical price chart
AKBA stock reached 52-week highs on December at $10.45, and all-time highs 2014-06-20 with a price of 31.
Akebia stock price target is $16.20Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we found 5 price targets for Akebia Therapeutics stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-6||HC Wainwright||Lowers Target||$19.00||$17.00||-10.5%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Akebia presented its financial report, posting an astounding growth for the Earnings per Share (EPS). Analyst were expecting $-0.27 per share, but Akebia Therapeutics posted $-0.91.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw an amazing gain of 14.63% to $207.74 million USD. By contrast, its income margin (compared to revenues) plummed to -69.12%, that is $-143.59 million.
|2016||$1.54 M||-||$-135.75 M-8843.5%||-|
|2017||$181 M||11,706.32%||$-73.67 M-40.7%||-45.73%|
|2018||$208 M||14.63%||$-143.59 M-69.1%||94.90%|
Quarterly financial resultsAkebia posted $59.85 M in sales for 2018-Q4, a 12.57% up compared to previous quarter. Reported quarter earnings marked $-60.05 million with a profit margin of -100.34%. Profit margin plunged a -51.35% compared to previous quarter when profit margin was -48.99%. When comparing turnover to same quarter last year, Akebia Therapeutics sales marked a hair-raising decrease and collapsed a -31.46%. Looking back to recent quarterly results, Akebia Therapeutics posted 3 negative quarters in a row.
|2017-Q1||$21 M||-||$-44.54 M-213.4%||-|
|2017-Q2||$29 M||36.66%||$-21.52 M-75.5%||-51.68%|
|2017-Q3||$41 M||44.75%||$-23.13 M-56.0%||7.50%|
|2017-Q4||$87 M||111.51%||$12.28 M14.1%||-153.08%|
|2018-Q1||$46 M||-47.40%||$-23.42 M-51.0%||-290.70%|
|2018-Q2||$49 M||6.23%||$-34.07 M-69.8%||45.48%|
|2018-Q3||$53 M||8.97%||$-26.05 M-49.0%||-23.55%|
|2018-Q4||$60 M||12.57%||$-60.05 M-100.3%||130.56%|
Akebia ownershipWhen you are planning to buy a stock, it's always worth to check its ownership structure.
Akebia Therapeutics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 8.23% of all shares.
In case of Akebia Therapeutics stock, 70.12% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AKBA stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Akebia:
|Market cap||$702.9 M||$138.9 B||$367.0 B||$3.6 B||$210.6 B|
|Total shares||118.9 M||594.2 M||2,630.0 M||175.9 M||2,290.0 M|
|Float shares||91.4 M||592.9 M||2,630.0 M||174.1 M||2,130.0 M|
|- Institutional holdings (%)||70.1%||81.9%||69.2%||96.2%||11.7%|
|- Insider holdings (%)||8.2%||0.2%||0.1%||0.9%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, December 6th, 2019|
|Day range||$5.72 - $6.22|
|Average true range||$0.61|
|50d mov avg||$4.19|
|100d mov avg||$4.25|
|200d mov avg||$5.16|
Akebia performanceTo measure stock performance is always good to benchmark with competitors or related stocks. In the following table, we compare Akebia Therapeutics performance to Amgen, , Nektar and Novartis: